296 related articles for article (PubMed ID: 29944140)
1. TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence.
Puig I; Tenbaum SP; Chicote I; Arqués O; Martínez-Quintanilla J; Cuesta-Borrás E; Ramírez L; Gonzalo P; Soto A; Aguilar S; Eguizabal C; Caratù G; Prat A; Argilés G; Landolfi S; Casanovas O; Serra V; Villanueva A; Arroyo AG; Terracciano L; Nuciforo P; Seoane J; Recio JA; Vivancos A; Dienstmann R; Tabernero J; Palmer HG
J Clin Invest; 2018 Aug; 128(9):3887-3905. PubMed ID: 29944140
[TBL] [Abstract][Full Text] [Related]
2. A Label Retaining System to Capture Slow-Cycling Cancer Cells.
Puig I; Palmer HG
Methods Mol Biol; 2022; 2535():85-92. PubMed ID: 35867224
[TBL] [Abstract][Full Text] [Related]
3. PML Recruits TET2 to Regulate DNA Modification and Cell Proliferation in Response to Chemotherapeutic Agent.
Song C; Wang L; Wu X; Wang K; Xie D; Xiao Q; Li S; Jiang K; Liao L; Yates JR; Lee JD; Yang Q
Cancer Res; 2018 May; 78(10):2475-2489. PubMed ID: 29735542
[TBL] [Abstract][Full Text] [Related]
4. Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer.
Wu D; Hu D; Chen H; Shi G; Fetahu IS; Wu F; Rabidou K; Fang R; Tan L; Xu S; Liu H; Argueta C; Zhang L; Mao F; Yan G; Chen J; Dong Z; Lv R; Xu Y; Wang M; Ye Y; Zhang S; Duquette D; Geng S; Yin C; Lian CG; Murphy GF; Adler GK; Garg R; Lynch L; Yang P; Li Y; Lan F; Fan J; Shi Y; Shi YG
Nature; 2018 Jul; 559(7715):637-641. PubMed ID: 30022161
[TBL] [Abstract][Full Text] [Related]
5. TET2 and DNMT3A mutations and exceptional response to 4'-thio-2'-deoxycytidine in human solid tumor models.
Yang SX; Hollingshead M; Rubinstein L; Nguyen D; Larenjeira ABA; Kinders RJ; Difilippantonio M; Doroshow JH
J Hematol Oncol; 2021 May; 14(1):83. PubMed ID: 34039392
[TBL] [Abstract][Full Text] [Related]
6. TET2-Dependent Hydroxymethylome Plasticity Reduces Melanoma Initiation and Progression.
Bonvin E; Radaelli E; Bizet M; Luciani F; Calonne E; Putmans P; Nittner D; Singh NK; Santagostino SF; Petit V; Larue L; Marine JC; Fuks F
Cancer Res; 2019 Feb; 79(3):482-494. PubMed ID: 30538121
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic silencing of TET2 and TET3 induces an EMT-like process in melanoma.
Gong F; Guo Y; Niu Y; Jin J; Zhang X; Shi X; Zhang L; Li R; Chen L; Ma RZ
Oncotarget; 2017 Jan; 8(1):315-328. PubMed ID: 27852070
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer.
Tucker DW; Getchell CR; McCarthy ET; Ohman AW; Sasamoto N; Xu S; Ko JY; Gupta M; Shafrir A; Medina JE; Lee JJ; MacDonald LA; Malik A; Hasselblatt KT; Li W; Zhang H; Kaplan SJ; Murphy GF; Hirsch MS; Liu JF; Matulonis UA; Terry KL; Lian CG; Dinulescu DM
Clin Cancer Res; 2018 Mar; 24(6):1389-1401. PubMed ID: 29263182
[No Abstract] [Full Text] [Related]
9. MYC deregulates TET1 and TET2 expression to control global DNA (hydroxy)methylation and gene expression to maintain a neoplastic phenotype in T-ALL.
Poole CJ; Lodh A; Choi JH; van Riggelen J
Epigenetics Chromatin; 2019 Jul; 12(1):41. PubMed ID: 31266538
[TBL] [Abstract][Full Text] [Related]
10. TET2 is a component of the estrogen receptor complex and controls 5mC to 5hmC conversion at estrogen receptor cis-regulatory regions.
Broome R; Chernukhin I; Jamieson S; Kishore K; Papachristou EK; Mao SQ; Tejedo CG; Mahtey A; Theodorou V; Groen AJ; D'Santos C; Balasubramanian S; Farcas AM; Siersbæk R; Carroll JS
Cell Rep; 2021 Feb; 34(8):108776. PubMed ID: 33626359
[TBL] [Abstract][Full Text] [Related]
11. Induction of DEAD Box helicase 5 in early adipogenesis is regulated by Ten-eleven translocation 2.
Cho M; Lee E; Shon J; Choi MJ; Park JH; Park YJ
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Jul; 1865(7):158684. PubMed ID: 32169654
[TBL] [Abstract][Full Text] [Related]
12. Values of 5mC, 5hmC, and TET2 for identifying the presence and progression of breast precancerous lesion.
Zhang Z; Jin Y; Zhang W; Chu C; Zhang K; Gao X; Zhou J; Zou L; Tang F; Wang H; Zou Q
J Clin Lab Anal; 2020 May; 34(5):e23162. PubMed ID: 31867779
[TBL] [Abstract][Full Text] [Related]
13. TET2-mediated 5-hydroxymethylcytosine induces genetic instability and mutagenesis.
Mahfoudhi E; Talhaoui I; Cabagnols X; Della Valle V; Secardin L; Rameau P; Bernard OA; Ishchenko AA; Abbes S; Vainchenker W; Saparbaev M; Plo I
DNA Repair (Amst); 2016 Jul; 43():78-88. PubMed ID: 27289557
[TBL] [Abstract][Full Text] [Related]
14. The TET2 interactors and their links to hematological malignancies.
Pan F; Weeks O; Yang FC; Xu M
IUBMB Life; 2015 Jun; 67(6):438-45. PubMed ID: 26099018
[TBL] [Abstract][Full Text] [Related]
15. TET2-Mediated Spatiotemporal Changes of 5-Hydroxymethylcytosine During Organogenesis in the Late Mouse Fetus.
Li X; Xie F; Jin J; Wu Y; Luo Z; Zhang F; Zhang S; Chen D; Liu A
Anat Rec (Hoboken); 2019 Jun; 302(6):954-963. PubMed ID: 30369084
[TBL] [Abstract][Full Text] [Related]
16. p53-dependent autophagic degradation of TET2 modulates cancer therapeutic resistance.
Zhang J; Tan P; Guo L; Gong J; Ma J; Li J; Lee M; Fang S; Jing J; Johnson G; Sun D; Cao WM; Dashwood R; Han L; Zhou Y; Dong WG; Huang Y
Oncogene; 2019 Mar; 38(11):1905-1919. PubMed ID: 30390073
[TBL] [Abstract][Full Text] [Related]
17. Association of high 5-hydroxymethylcytosine levels with Ten Eleven Translocation 2 overexpression and inflammation in Sjögren's syndrome patients.
Lagos C; Carvajal P; Castro I; Jara D; González S; Aguilera S; Barrera MJ; Quest AFG; Bahamondes V; Molina C; Urzúa U; Hermoso MA; Leyton C; González MJ
Clin Immunol; 2018 Nov; 196():85-96. PubMed ID: 29894742
[TBL] [Abstract][Full Text] [Related]
18. Acetylation Enhances TET2 Function in Protecting against Abnormal DNA Methylation during Oxidative Stress.
Zhang YW; Wang Z; Xie W; Cai Y; Xia L; Easwaran H; Luo J; Yen RC; Li Y; Baylin SB
Mol Cell; 2017 Jan; 65(2):323-335. PubMed ID: 28107650
[TBL] [Abstract][Full Text] [Related]
19. Changes in DNA 5-Hydroxymethylcytosine Levels and the Underlying Mechanism in Non-functioning Pituitary Adenomas.
Xu Y; Niu Y; Deng K; Pan H; Feng F; Gong F; Tong WM; Chen S; Lu L; Wang R; You H; Yao Y; Zhu H
Front Endocrinol (Lausanne); 2020; 11():361. PubMed ID: 32774324
[TBL] [Abstract][Full Text] [Related]
20. A role for
Barazeghi E; Gill AJ; Sidhu S; Norlén O; Dina R; Palazzo FF; Hellman P; Stålberg P; Westin G
Endocr Relat Cancer; 2017 Jul; 24(7):329-338. PubMed ID: 28642344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
